Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.01
GILD's Cash to Debt is ranked higher than
60% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. GILD: 1.01 )
GILD' s 10-Year Cash to Debt Range
Min: 0.15   Max: No Debt
Current: 1.01

Equity to Asset 0.53
GILD's Equity to Asset is ranked higher than
65% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. GILD: 0.53 )
GILD' s 10-Year Equity to Asset Range
Min: 0.21   Max: 0.95
Current: 0.53

0.21
0.95
Interest Coverage 14.74
GILD's Interest Coverage is ranked higher than
55% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GILD: 14.74 )
GILD' s 10-Year Interest Coverage Range
Min: 5.85   Max: 2509.2
Current: 14.74

5.85
2509.2
F-Score: 7
Z-Score: 9.33
M-Score: -1.90
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 58.62
GILD's Operating margin (%) is ranked higher than
98% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -55.17 vs. GILD: 58.62 )
GILD' s 10-Year Operating margin (%) Range
Min: -1185.19   Max: 54.68
Current: 58.62

-1185.19
54.68
Net-margin (%) 45.45
GILD's Net-margin (%) is ranked higher than
97% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -51.98 vs. GILD: 45.45 )
GILD' s 10-Year Net-margin (%) Range
Min: -1014.81   Max: 40.13
Current: 45.45

-1014.81
40.13
ROE (%) 70.99
GILD's ROE (%) is ranked higher than
98% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -25.77 vs. GILD: 70.99 )
GILD' s 10-Year ROE (%) Range
Min: -49.14   Max: 61.24
Current: 70.99

-49.14
61.24
ROA (%) 35.33
GILD's ROA (%) is ranked higher than
98% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -19.98 vs. GILD: 35.33 )
GILD' s 10-Year ROA (%) Range
Min: -30.31   Max: 32.56
Current: 35.33

-30.31
32.56
ROC (Joel Greenblatt) (%) 521.59
GILD's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -210.62 vs. GILD: 521.59 )
GILD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -127.04   Max: 187.3
Current: 521.59

-127.04
187.3
Revenue Growth (%) 13.30
GILD's Revenue Growth (%) is ranked higher than
86% of the 653 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. GILD: 13.30 )
GILD' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 122.4
Current: 13.3

0
122.4
EBITDA Growth (%) 5.40
GILD's EBITDA Growth (%) is ranked higher than
84% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. GILD: 5.40 )
GILD' s 10-Year EBITDA Growth (%) Range
Min: -20.6   Max: 119
Current: 5.4

-20.6
119
EPS Growth (%) 2.90
GILD's EPS Growth (%) is ranked higher than
83% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. GILD: 2.90 )
GILD' s 10-Year EPS Growth (%) Range
Min: -20.6   Max: 153.3
Current: 2.9

-20.6
153.3
» GILD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

GILD Guru Trades in Q4 2013

Paul Tudor Jones 7,997 sh (New)
Louis Moore Bacon 300,000 sh (New)
Ray Dalio 38,621 sh (New)
John Rogers 324,302 sh (+396.9%)
Daniel Loeb 1,500,000 sh (+200%)
Pioneer Investments 2,884,918 sh (+70.12%)
Steven Cohen 63,000 sh (+27.71%)
Julian Robertson 320,001 sh (+25.84%)
Jeremy Grantham 3,386,737 sh (+15.89%)
Mario Gabelli 33,605 sh (+7.35%)
Ken Fisher 1,010,705 sh (+3.41%)
Ronald Muhlenkamp 192,795 sh (+2.89%)
Stanley Druckenmiller 610,700 sh (unchged)
Jean-Marie Eveillard 400 sh (unchged)
Caxton Associates Sold Out
George Soros Sold Out
John Hussman Sold Out
Mariko Gordon 15,452 sh (-3.02%)
RS Investment Management 162,480 sh (-14.7%)
David Rolfe 1,800,984 sh (-28.36%)
Vanguard Health Care Fund 4,630,700 sh (-28.62%)
John Griffin 620,000 sh (-68.21%)
» More
Q1 2014

GILD Guru Trades in Q1 2014

John Burbank 3,619 sh (New)
George Soros 50,000 sh (New)
Caxton Associates 50,000 sh (New)
Jim Simons 189,353 sh (New)
Louis Moore Bacon 2,239,590 sh (+646.53%)
Ray Dalio 247,721 sh (+541.42%)
Steven Cohen 207,778 sh (+229.81%)
Paul Tudor Jones 10,805 sh (+35.11%)
Mario Gabelli 44,240 sh (+31.65%)
John Rogers 397,273 sh (+22.5%)
Mariko Gordon 18,089 sh (+17.07%)
Pioneer Investments 3,349,807 sh (+16.11%)
RS Investment Management 180,214 sh (+10.91%)
Julian Robertson 345,320 sh (+7.91%)
David Rolfe 1,907,287 sh (+5.9%)
Caxton Associates 60,000 sh (unchged)
Paul Tudor Jones 75,000 sh (unchged)
Jean-Marie Eveillard 400 sh (unchged)
John Griffin Sold Out
Stanley Druckenmiller Sold Out
Daniel Loeb Sold Out
Ronald Muhlenkamp 192,015 sh (-0.4%)
Ken Fisher 601,758 sh (-40.46%)
Vanguard Health Care Fund 2,713,300 sh (-41.41%)
Jeremy Grantham 516,946 sh (-84.74%)
» More
Q2 2014

GILD Guru Trades in Q2 2014

Ken Heebner 1,710,000 sh (New)
Joel Greenblatt 466,853 sh (New)
Alan Fournier 2,070,000 sh (New)
Ken Fisher 975,483 sh (+62.11%)
John Rogers 638,734 sh (+60.78%)
Ray Dalio 349,821 sh (+41.22%)
Julian Robertson 443,911 sh (+28.55%)
Pioneer Investments 3,899,022 sh (+16.4%)
Mario Gabelli 49,170 sh (+11.14%)
RS Investment Management 192,614 sh (+6.88%)
John Burbank 3,774 sh (+4.28%)
Caxton Associates 100,000 sh (unchged)
Jean-Marie Eveillard 400 sh (unchged)
David Rolfe Sold Out
Caxton Associates Sold Out
Louis Moore Bacon Sold Out
George Soros Sold Out
Jim Simons 166,648 sh (-11.99%)
Paul Tudor Jones 9,304 sh (-13.89%)
Ronald Muhlenkamp 144,715 sh (-24.63%)
Mariko Gordon 11,654 sh (-35.57%)
Vanguard Health Care Fund 1,633,700 sh (-39.79%)
Jeremy Grantham 10,600 sh (-97.95%)
» More
Q3 2014

GILD Guru Trades in Q3 2014

Vanguard Health Care Fund 379,200 sh (-76.79%)
» More
» Details

Insider Trades

Latest Guru Trades with GILD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2014-09-30 Reduce -76.79%0.28%$85.07 - $109.43 $ 11214%379200
Ken Heebner 2014-06-30 New Buy3.8%$65.48 - $83.02 $ 11244%1710000
Julian Robertson 2014-06-30 Add 28.55%2.98%$65.48 - $83.02 $ 11244%443911
Ronald Muhlenkamp 2014-06-30 Reduce -24.63%0.59%$65.48 - $83.02 $ 11244%144715
Joel Greenblatt 2014-06-30 New Buy0.48%$65.48 - $83.02 $ 11244%466853
John Rogers 2014-06-30 Add 60.78%0.25%$65.48 - $83.02 $ 11244%638734
Vanguard Health Care Fund 2014-06-30 Reduce -39.79%0.21%$65.48 - $83.02 $ 11244%1633700
Ken Fisher 2014-06-30 Add 62.11%0.07%$65.48 - $83.02 $ 11244%975483
Ray Dalio 2014-06-30 Add 41.22%0.06%$65.48 - $83.02 $ 11244%349821
George Soros 2014-06-30 Sold Out 0.04%$65.48 - $83.02 $ 11244%0
Mariko Gordon 2014-06-30 Reduce -35.57%0.02%$65.48 - $83.02 $ 11244%11654
Daniel Loeb 2014-03-31 Sold Out 1.9%$68.55 - $83.95 $ 11243%0
Julian Robertson 2014-03-31 Add 7.91%0.59%$68.55 - $83.95 $ 11243%345320
John Griffin 2014-03-31 Sold Out 0.48%$68.55 - $83.95 $ 11243%0
Vanguard Health Care Fund 2014-03-31 Reduce -41.41%0.46%$68.55 - $83.95 $ 11243%2713300
Ray Dalio 2014-03-31 Add 541.42%0.12%$68.55 - $83.95 $ 11243%247721
Ken Fisher 2014-03-31 Reduce -40.46%0.07%$68.55 - $83.95 $ 11243%601758
John Rogers 2014-03-31 Add 22.5%0.06%$68.55 - $83.95 $ 11243%397273
George Soros 2014-03-31 New Buy0.04%$68.55 - $83.95 $ 11243%50000
John Burbank 2014-03-31 New Buy0.01%$68.55 - $83.95 $ 11243%3619
Mario Gabelli 2014-03-31 Add 31.65%$68.55 - $83.95 $ 11243%44240
Julian Robertson 2013-12-31 Add 25.84%1.52%$58.9 - $75.2 $ 11261%320001
Daniel Loeb 2013-12-31 Add 200%1.27%$58.9 - $75.2 $ 11261%1500000
John Griffin 2013-12-31 Reduce -68.21%1.02%$58.9 - $75.2 $ 11261%620000
John Hussman 2013-12-31 Sold Out 0.86%$58.9 - $75.2 $ 11261%0
Vanguard Health Care Fund 2013-12-31 Reduce -28.62%0.4%$58.9 - $75.2 $ 11261%4630700
John Rogers 2013-12-31 Add 396.9%0.24%$58.9 - $75.2 $ 11261%324302
Ray Dalio 2013-12-31 New Buy0.02%$58.9 - $75.2 $ 11261%38621
George Soros 2013-12-31 Sold Out 0.02%$58.9 - $75.2 $ 11261%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Gilead Sciences Inc

Wedgewood Partners' David Rolfe Comments on Gilead Sciences - Nov 12, 2012

Gilead Sciences (GILD) was among our top performers during the third quarter. We believe that the stock's strong performance over the past three months, as well as the past year is quite warranted, as the company is on the cutting edge in developing a cure for the hepatitis C virus (HCV). The Company’s journey down this path began last November with their $11 billion purchase of Pharmasset, Inc. Pharmasset’s flagship drug candidate (PSI-7977, now GS-7977) is undergoing trials indicated for all-oral treatment of HCV and if ultimately approved by the FDA, Gilead could possess a multi-year, multi-billion dollar revenue opportunity. We believe that the market, more recently, has better recognized this opportunity, so we trimmed our positions during the quarter.

From Wedgewood Partners Third Quarter 2012 Review and Outlook.


Check out David Rolfe latest stock trades

Top Ranked Articles about Gilead Sciences Inc

Weekly CFO Sells Highlight: Affiliated Managers Group Inc., Gilead Sciences Inc., L-3 Communications Holdings Inc.
According to GuruFocus Insider Data, the recent CFO sales were: Affiliated Managers Group Inc., Gilead Sciences Inc. and L-3 Communications Holdings Inc. Read more...
Weekly Insider Sells Highlight: ATHN, GILD, JPM, WAG
According to GuruFocus Insider Data, the largest insider sells during the past week were: AthenaHealth Inc, Gilead Sciences Inc, JPMorgan Chase & Co, and Walgreen Company. Read more...
Weekly CFO Sells Highlight: Gilead Sciences Inc., Micron Technology Inc., Adobe Systems Inc.
According to GuruFocus Insider Data, the recent CFO sales were: Gilead Sciences Inc., Micron Technology Inc. and Adobe Systems Inc. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 24.90
GILD's P/E(ttm) is ranked higher than
95% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GILD: 24.90 )
GILD' s 10-Year P/E(ttm) Range
Min: 9.69   Max: 45.41
Current: 24.9

9.69
45.41
P/B 10.50
GILD's P/B is ranked higher than
64% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.60 vs. GILD: 10.50 )
GILD' s 10-Year P/B Range
Min: 4.16   Max: 18.59
Current: 10.5

4.16
18.59
P/S 10.90
GILD's P/S is ranked higher than
79% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 19.97 vs. GILD: 10.90 )
GILD' s 10-Year P/S Range
Min: 3.48   Max: 16.44
Current: 10.9

3.48
16.44
PFCF 27.20
GILD's PFCF is ranked higher than
96% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GILD: 27.20 )
GILD' s 10-Year PFCF Range
Min: 8.33   Max: 68.49
Current: 27.2

8.33
68.49
EV-to-EBIT 17.46
GILD's EV-to-EBIT is ranked higher than
95% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GILD: 17.46 )
GILD' s 10-Year EV-to-EBIT Range
Min: -103.9   Max: 473.4
Current: 17.46

-103.9
473.4
PEG 3.09
GILD's PEG is ranked higher than
96% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GILD: 3.09 )
GILD' s 10-Year PEG Range
Min: 0.37   Max: 4.23
Current: 3.09

0.37
4.23
Shiller P/E 51.70
GILD's Shiller P/E is ranked higher than
95% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GILD: 51.70 )
GILD' s 10-Year Shiller P/E Range
Min: 18.04   Max: 1840.8
Current: 51.7

18.04
1840.8
Current Ratio 2.42
GILD's Current Ratio is ranked higher than
66% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. GILD: 2.42 )
GILD' s 10-Year Current Ratio Range
Min: 1.15   Max: 20.42
Current: 2.42

1.15
20.42
Quick Ratio 2.09
GILD's Quick Ratio is ranked higher than
66% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. GILD: 2.09 )
GILD' s 10-Year Quick Ratio Range
Min: 0.82   Max: 20.42
Current: 2.09

0.82
20.42

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 45.50
GILD's Price/Tangible Book is ranked higher than
62% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9.08 vs. GILD: 45.50 )
GILD' s 10-Year Price/Tangible Book Range
Min: 1.86   Max: 131.22
Current: 45.5

1.86
131.22
Price/DCF (Projected) 2.80
GILD's Price/DCF (Projected) is ranked higher than
94% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GILD: 2.80 )
GILD' s 10-Year Price/DCF (Projected) Range
Min: 0.77   Max: 20.81
Current: 2.8

0.77
20.81
Price/Median PS Value 1.10
GILD's Price/Median PS Value is ranked higher than
82% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 1.92 vs. GILD: 1.10 )
GILD' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 4.65
Current: 1.1

0.4
4.65
Price/Peter Lynch Fair Value 1.80
GILD's Price/Peter Lynch Fair Value is ranked higher than
98% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GILD: 1.80 )
GILD' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.4   Max: 9.13
Current: 1.8

0.4
9.13
Price/Graham Number 6.80
GILD's Price/Graham Number is ranked higher than
87% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GILD: 6.80 )
GILD' s 10-Year Price/Graham Number Range
Min: 1.59   Max: 11.85
Current: 6.8

1.59
11.85
Earnings Yield (Greenblatt) 5.80
GILD's Earnings Yield (Greenblatt) is ranked higher than
95% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. GILD: 5.80 )
GILD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 15
Current: 5.8

0.2
15
Forward Rate of Return (Yacktman) 15.49
GILD's Forward Rate of Return (Yacktman) is ranked higher than
95% of the 767 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. GILD: 15.49 )
GILD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.9   Max: 43.7
Current: 15.49

-0.9
43.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, BIIB, CELG, CMXHY » details
Traded in other countries:GIS.Germany, GILD.Mexico
Gilead Sciences, Inc. was incorporated in Delaware on June 22, 1987. The Company is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors. With each new discovery and experimental drug candidate, it seeks to improve the care of patients suffering from life-threatening diseases around the world. The Company's primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases such as hepatitis B and C and serious cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Australia. It markets products in the HIV/AIDS, liver diseases, respiratory and cardiovascular/metabolic therapeutic areas. The Company's products comprise Truvada is an oral formulation dosed once a day as part of combination therapy to treat human immunodeficiency virus infection in adults. Atripla is an oral formulation dosed once a day for the treatment of HIV infection in adults. Viread is an oral formulation of a nucleotide analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. Emtriva is an oral formulation of a nucleoside analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. Hepsera is an oral formulation of a nucleotide analogue polymerase inhibitor, dosed once a day to treat chronic hepatitis B. AmBisome is a proprietary liposomal formulation of amphotericin B, an antifungal agent to treat serious invasive fungal infections caused by various fungal species. Letairis is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension in patients with WHO Class II or III symptoms to improve exercise capacity and delay clinical worsening. Ranexa is indicated for the treatment of chronic angina. Vistide is an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS. Cayston is an inhaled antibiotic as a treatment to improve respiratory systems in cystic fibrosis patients with Pseudomonas aeruginosa. The Company has U.S. and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, the Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland, Turkey, the United Kingdom and the United States. The Company sells and distributes Truvada, Viread, Emtriva, Hepsera and AmBisome in Asia, Australia, Europe, Latin America, the Middle East and New Zealand either through its commercial teams, third party distributors or corporate partners. The Company's products and development programs target a number of areas, including viral, fungal, respiratory and cardiovascular diseases. The Company's products compete with other available products based mainly on: efficacy; safety; tolerability; acceptance by docto
» More Articles for GILD

Headlines

Articles On GuruFocus.com
Gilead Sciences has Multiple Growth Drivers Oct 31 2014 
Is Gilead Sciences a Worthy Investment? Oct 30 2014 
Gilead Sciences – From The Long Term Perspective Oct 08 2014 
There's More to Gilead Sciences than a Successful Drug Sep 26 2014 
A Few Reasons Why AbbVie's Momentum Will Continue Sep 25 2014 
Gilead Sciences: Up Over 1,100% And Still Cheap Sep 09 2014 
After Reaching All-Time Highs, How Can Gilead Sciences Continue growing? Aug 27 2014 
Everything's Going Right for Gilead Sciences Aug 26 2014 
New Magic Formula Stocks From Joel Greenblatt: CBI, DAL, GILD, MNST, ROST, LUV Aug 18 2014 
Julian Robertson Buys Tableau Software, Facebook, Netflix, Sells Ulta Salon, EBay, EQT Aug 14 2014 


More From Other Websites
Fundamentals, Technicals Still Intact At Gilead Sciences Oct 31 2014
Today's Market Thorns, Roses, All Time Highs, and ETF All Time Highs Oct 31 2014
AbbVie Beats Q3 Earnings Estimates, Raises Guidance Oct 31 2014
Gilead Sciences: Harvoni Still Selling Like Hotcakes Oct 31 2014
[video]Netflix and Gilead Will See More Gains, Says Thornburg Value Manager Oct 30 2014
Veeva Systems Flies High On Cloud For Life Sciences Oct 30 2014
Market Thorns, Roses, All Time Highs, and ETF All Time Highs... Oct 30 2014
Facebook, Twitter, Amazon And Gilead: Musketeers Wielding Blunted Swords? Oct 30 2014
[video]Phibro, Gilead Will See More Gains Says Thornburg Value Manager Oct 30 2014
[$$] Gilead: Buy the Dip Oct 29 2014
4 Stocks, 4 trades: GT, PNRA, HSY & GILD Oct 29 2014
Limited downside seen in Gilead Oct 29 2014
Gilead Sciences Suffers 'Sloppy' Quarter on 'Unimportant' Sovaldi Sales Oct 29 2014
Gilead Sciences (GILD) Stock Declines After Weak Third-Quarter Results Oct 29 2014
Stocks Stage Mixed Start; Facebook Drags Down Nasdaq Oct 29 2014
Gilead Sciences (GILD) Earnings Report: Q3 2014 Conference Call Transcript Oct 29 2014
Gilead Beats on Q3 Earnings, Sovaldi Sales Fall Sequentially Oct 29 2014
Gilead Sciences Earnings Miss on Dwindling Sovaldi Sales Oct 29 2014
[$$] Sales of Gilead’s Pricey Hepatitis Drug Slow Oct 28 2014
Gilead (GILD) Posts Weak Earnings; Stock Falls 4% After-Hours Oct 28 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK